|
1
|
Foulkes WD, Smith IE and Reis-Filho JS:
Triple-negative breast cancer. N Engl J Med. 363:1938–1948. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Adams JM and Cory S: The Bcl-2 apoptotic
switch in cancer development and therapy. Oncogene. 26:1324–1337.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Adams JM and Cory S: The BCL-2 arbiters of
apoptosis and their growing role as cancer targets. Cell Death
Differ. 25:27–36. 2018. View Article : Google Scholar
|
|
5
|
Mohammad RM, Muqbil I, Lowe L, Yedjou C,
Hsu HY, Lin LT, Siegelin MD, Fimognari C, Kumar NB, Dou QP, et al:
Broad targeting of resistance to apoptosis in cancer. Semin Cancer
Biol. 35(Suppl): S78–S103. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kang MH and Reynolds CP: Bcl-2 inhibitors:
Targeting mitochondrial apoptotic pathways in cancer therapy. Clin
Cancer Res. 15:1126–1132. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ertel F, Nguyen M, Roulston A and Shore
GC: Programming cancer cells for high expression levels of Mcl1.
EMBO Rep. 14:328–336. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Craig RW: MCL1 provides a window on the
role of the BCL2 family in cell proliferation, differentiation and
tumorigenesis. Leukemia. 16:444–454. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Beroukhim R, Mermel CH, Porter D, Wei G,
Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J,
Urashima M, et al: The landscape of somatic copy-number alteration
across human cancers. Nature. 463:899–905. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ding Q, He X, Hsu JM, Xia W, Chen CT, Li
LY, Lee DF, Liu JC, Zhong Q, Wang X and Hung MC: Degradation of
Mcl-1 by beta-TrCP mediates glycogen synthase kinase 3-induced
tumor suppression and chemosensitization. Mol Cell Biol.
27:4006–4017. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Young AI, Timpson P, Gallego-Ortega D,
Ormandy CJ and Oakes SR: Myeloid cell leukemia 1 (MCL-1), an
unexpected modulator of protein kinase signaling during invasion.
Cell Adh Migr. 12:513–523. 2018. View Article : Google Scholar
|
|
12
|
Woo SM, Min KJ, Seo BR, Seo YH, Jeong YJ
and Kwon TK: YM155 enhances ABT-737-mediated apoptosis through
Mcl-1 downregulation in Mcl-1-overexpressed cancer cells. Mol Cell
Biochem. 429:91–102. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Caenepeel S, Brown SP, Belmontes B, Moody
G, Keegan KS, Chui D, Whittington DA, Huang X, Poppe L, Cheng AC,
et al: AMG 176, a selective MCL1 inhibitor, is effective in
hematologic cancer models alone and in combination with established
therapies. Cancer Discov. 8:1582–1597. 2018.PubMed/NCBI
|
|
14
|
Ramsey HE, Fischer MA, Lee T, Gorska AE,
Arrate MP, Fuller L, Boyd KL, Strickland SA, Sensintaffar J, Hogdal
LJ, et al: A novel MCL1 inhibitor combined with venetoclax rescues
venetoclaxresistant acute myelogenous leukemia. Cancer Discov.
8:1566–1581. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wainwright M: Acridine-a neglected
antibacterial chromophore. J Antimicrob Chemother. 47:1–13. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lee K, Zhang H, Qian DZ, Rey S, Liu JO and
Semenza GL: Acriflavine inhibits HIF-1 dimerization, tumor growth,
and vascularization. Proc Natl Acad Sci USA. 106:17910–17915. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang L, Huang G, Li X, Zhang Y, Jiang Y,
Shen J, Liu J, Wang Q, Zhu J, Feng X, et al: Hypoxia induces
epithelial-mesenchymal transition via activation of SNAI1 by
hypoxia-inducible factor -1α in hepatocellular carcinoma. BMC
Cancer. 13:1082013. View Article : Google Scholar
|
|
18
|
Lee CJ, Yue CH, Lin YJ, Lin YY, Kao SH,
Liu JY and Chen YH: Antitumor activity of acriflavine in lung
adenocarcinoma cell line A549. Anticancer Res. 34:6467–6472.
2014.PubMed/NCBI
|
|
19
|
Lee CJ, Yue CH, Lin YY, Wu JC and Liu JY:
Antitumor activity of acriflavine in human hepatocellular carcinoma
cells. Anticancer Res. 34:3549–3556. 2014.PubMed/NCBI
|
|
20
|
Dekervel J, Bulle A, Windmolders P,
Lambrechts D, Van Cutsem E, Verslype C and van Pelt J: Acriflavine
inhibits acquired drug resistance by blocking the
epithelial-to-mesenchymal transition and the unfolded protein
response. Transl Oncol. 10:59–69. 2017. View Article : Google Scholar :
|
|
21
|
Mangraviti A, Raghavan T, Volpin F, Skuli
N, Gullotti D, Zhou J, Asnaghi L, Sankey E, Liu A, Wang Y, et al:
HIF-1α-targeting acriflavine provides long term survival and
radiological tumor response in brain cancer therapy. Sci Rep.
7:149782017. View Article : Google Scholar
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2-(Delta Delta C(T) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
23
|
Jeong SH, Kim HK, Song IS, Lee SJ, Ko KS,
Rhee BD, Kim N, Mishchenko NP, Fedoryev SA, Stonik VA and Han J:
Echinochrome A protects mitochondrial function in cardiomyocytes
against cardiotoxic drugs. Mar Drugs. 12:2922–2936. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chou TC: Theoretical basis, experimental
design, and computerized simulation of synergism and antagonism in
drug combination studies. Pharmacol Rev. 58:621–681. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ashton JC: Drug combination studies and
their synergy quantification using the Chou-Talalay method-letter.
Cancer Res. 75:24002015. View Article : Google Scholar
|
|
26
|
Williams MM, Lee L, Hicks DJ, Joly MM,
Elion D, Rahman B, McKernan C, Sanchez V, Balko JM, Stricker T, et
al: Key survival factor, Mcl-1, correlates with sensitivity to
combined Bcl-2/Bcl-xL blockade. Mol Cancer Res. 15:259–268. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Certo M, Del Gaizo Moore V, Nishino M, Wei
G, Korsmeyer S, Armstrong SA and Letai A: Mitochondria primed by
death signals determine cellular addiction to antiapoptotic BCL-2
family members. Cancer Cell. 9:351–365. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lovell JF, Billen LP, Bindner S,
Shamas-Din A, Fradin C, Leber B and Andrews DW: Membrane binding by
tBid initiates an ordered series of events culminating in membrane
permeabilization by Bax. Cell. 135:1074–1084. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kuwana T, Bouchier-Hayes L, Chipuk JE,
Bonzon C, Sullivan BA, Green DR and Newmeyer DD: BH3 domains of
BH3-only proteins differentially regulate Bax-mediated
mitochondrial membrane permeabilization both directly and
indirectly. Mol Cell. 17:525–535. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Willis SN, Chen L, Dewson G, Wei A, Naik
E, Fletcher JI, Adams JM and Huang DC: Proapoptotic bak is
sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by
BH3-only proteins. Genes Dev. 19:1294–1305. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Edlich F, Banerjee S, Suzuki M, Cleland
MM, Arnoult D, Wang C, Neutzner A, Tjandra N and Youle RJ: Bcl-x(L)
retrotranslocates bax from the mitochondria into the cytosol. Cell.
145:104–116. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Oltersdorf T, Elmore SW, Shoemaker AR,
Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges
J, Hajduk PJ, et al: An inhibitor of Bcl-2 family proteins induces
regression of solid tumours. Nature. 435:677–681. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Souers AJ, Leverson JD, Boghaert ER,
Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH,
Fairbrother WJ, et al: ABT-199, a potent and selective BCL-2
inhibitor, achieves anti-tumor activity while sparing platelets.
Nat Med. 19:202–208. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bartlett NL: Highlights in lymphoma from
the 2013 American society of hematology annual meeting and
exposition: Commentary. Clin Adv Hematol Oncol. 12(Suppl 6): 18–23.
2014.PubMed/NCBI
|
|
35
|
Sieghart W, Losert D, Strommer S, Cejka D,
Schmid K, Rasoul-Rockenschaub S, Bodingbauer M, Crevenna R, Monia
BP, Peck-Radosavljevic M and Wacheck V: Mcl-1 overexpression in
hepatocellular carcinoma: A potential target for antisense therapy.
J Hepatol. 44:151–157. 2006. View Article : Google Scholar
|
|
36
|
LaBelle JL, Katz SG, Bird GH, Gavathiotis
E, Stewart ML, Lawrence C, Fisher JK, Godes M, Pitter K, Kung AL
and Walensky LD: A stapled BIM peptide overcomes apoptotic
resistance in hematologic cancers. J Clin Invest. 122:2018–2031.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Reiner T, de Las Pozas A, Parrondo R,
Palenzuela D, Cayuso W, Rai P and Perez-Stable C: Mcl-1 protects
prostate cancer cells from cell death mediated by
chemotherapy-induced DNA damage. Oncoscience. 2:703–715. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Young AI, Law AM, Castillo L, Chong S,
Cullen HD, Koehler M, Herzog S, Brummer T, Lee EF, Fairlie WD, et
al: MCL-1 inhibition provides a new way to suppress breast cancer
metastasis and increase sensitivity to dasatinib. Breast Cancer
Res. 18:1252016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zervantonakis IK, Iavarone C, Chen HY,
Selfors LM, Palakurthi S, Liu JF, Drapkin R, Matulonis U, Leverson
JD, Sampath D, et al: Systems analysis of apoptotic priming in
ovarian cancer identifies vulnerabilities and predictors of drug
response. Nat Commun. 8:3652017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Campbell KJ, Dhayade S, Ferrari N, Sims
AH, Johnson E, Mason SM, Dickson A, Ryan KM, Kalna G, Edwards J, et
al: MCL-1 is a prognostic indicator and drug target in breast
cancer. Cell Death Dis. 9:192018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Goodwin CM, Rossanese OW, Olejniczak ET
and Fesik SW: Myeloid cell leukemia-1 is an important apoptotic
survival factor in triple-negative breast cancer. Cell Death
Differ. 22:2098–2106. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Balko JM, Giltnane JM, Wang K, Schwarz LJ,
Young CD, Cook RS, Owens P, Sanders ME, Kuba MG, Sánchez V, et al:
Molecular profiling of the residual disease of triple-negative
breast cancers after neoadjuvant chemotherapy identifies actionable
therapeutic targets. Cancer Discov. 4:232–245. 2014. View Article : Google Scholar :
|
|
43
|
Ozretic P, Alvir I, Sarcevic B, Vujaskovic
Z, Rendic-Miocevic Z, Roguljic A and Beketic-Oreskovic L: Apoptosis
regulator Bcl-2 is an independent prognostic marker for worse
overall survival in triple-negative breast cancer patients. Int J
Biol Markers. 33:109–115. 2018. View Article : Google Scholar
|
|
44
|
Inuzuka H, Shaik S, Onoyama I, Gao D,
Tseng A, Maser RS, Zhai B, Wan L, Gutierrez A, Lau AW, et al:
SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for
ubiquitylation and destruction. Nature. 471:104–109. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wertz IE, Kusam S, Lam C, Okamoto T,
Sandoval W, Anderson DJ, Helgason E, Ernst JA, Eby M, Liu J, et al:
Sensitivity to antitubulin chemotherapeutics is regulated by MCL1
and FBW7. Nature. 471:110–114. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Leverson JD, Zhang H, Chen J, Tahir SK,
Phillips DC, Xue J, Nimmer P, Jin S, Smith M, Xiao Y, et al: Potent
and selective small-molecule MCL-1 inhibitors demonstrate on-target
cancer cell killing activity as single agents and in combination
with ABT-263 (navitoclax). Cell Death Dis. 6:e15902015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Pan R, Ruvolo VR, Wei J, Konopleva M, Reed
JC, Pellecchia M, Andreeff M and Ruvolo PP: Inhibition of Mcl-1
with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737
resistance in acute myeloid leukemia. Blood. 126:363–372. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Mojsa B, Lassot I and Desagher S: Mcl-1
ubiquitination: Unique regulation of an essential survival protein.
Cells. 3:418–437. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Goldie H, Walker M, Graham T and Williams
F: Topical effect of acriflavine compounds on growth and spread of
malignant cells. J Natl Cancer Inst. 23:841–855. 1959.PubMed/NCBI
|
|
50
|
Hassan S, Laryea D, Mahteme H, Felth J,
Fryknas M, Fayad W, Linder S, Rickardson L, Gullbo J, Graf W, et
al: Novel activity of acriflavine against colorectal cancer tumor
cells. Cancer Sci. 102:2206–2213. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Kim SG, Kim CW, Ahn ET, Lee KY, Hong EK,
Yoo BI and Han YB: Enhanced anti-tumour effects of acriflavine in
combination with guanosine in mice. J Pharm Pharmacol. 49:216–222.
1997. View Article : Google Scholar : PubMed/NCBI
|
